전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-3 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,047 programs
CGTLimited DatastaleShanghai Longyao Biotechnology …Phase 2

Mixed CD19/CD20 CAR-T Transfer (Mixed CD19/CD20 CAR-T Transfer)

Recurrent or Refractory B Cell Malignancy · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleNYU Langone HealthPhase 1

nivolumab (Opdivo, Mocetinostat Induction Phase + Ipilimumab + Nivolumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase1#monoclonal-antibody#NYU
Trials 1Status Discontinued
AntibodyLimited DatastaleNYU Langone HealthPhase 1

nivolumab (Opdivo, Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase1#monoclonal-antibody#NYU
Trials 1Status Discontinued
ADCLimited DatastaleMethylGene Inc.Phase 2

brentuximab vedotin (Adcetris, Mocetinostat Plus Brentuximab Vedotin)

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#antibody-drug-conjugate#MethylGene
Trials 1Status Active
CGTLimited DatastaleLiqun ZouPhase 1

Modified anti-CD19 CAR T cells (Modified anti-CD19 CAR T cells)

Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleAssistance Publique Hopitaux De…Phase 2

IPH2201 (Monalizumab, Monalizumab (IPH2201))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Assistance
Trials 1Status Recruiting
AntibodyLimited DatastaleIstituto Clinico HumanitasPhase 2

anti-NKG2A monoclonal antibody (Monalizumab, Monalizumab (anti-NKG2A monoclonal antibody))

Acute Myeloid Leukaemia; MDS (Myelodysplastic Syndrome) · Acute Myeloid Leukaemia

#AcuteMyeloidLeukaemia#Antibody#Phase2#monoclonal-antibody#MDSMyelodysplasticSyndrome+1
Trials 1Status Recruiting
AntibodyLimited DatastaleSWISS BIOPHARMA MED GmbHPhase 1

Monoclonal antibody (Mab, Monoclonal antibody, Monoclonal antibody (Mab) sB24M)

Pyoderma; Pyoderma Gangrenosum · Pyoderma

#Pyoderma#Antibody#Phase1#monoclonal-antibody#PyodermaGangrenosum+1
Trials 1Status Active
AntibodyLimited DatastalePresage BiosciencesPhase 1

nivolumab (Opdivo, Motolimod + Nivolumab)

HNSCC · HNSCC

#HNSCC#Antibody#Phase1#monoclonal-antibody#Presage
Trials 1Status Discontinued
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 1

Moxetumomab Pasudotox-tdfk (Moxetumomab Pasudotox-tdfk)

Hairy Cell Leukemia · Hairy Cell Leukemia

#HairyCellLeukemia#Antibody#Phase1#monoclonal-antibody#National
Trials 1Status Recruiting
AntibodyLimited DatastaleMayo ClinicPhase 2

Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine (Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine)

Fallopian Tube Carcinosarcoma; Primary Peritoneal Carcinosarcoma · Fallopian Tube Carcinosarcoma

#FallopianTubeCarcinosarcoma#Antibody#Phase2#monoclonal-antibody#PrimaryPeritonealCarcinosarcoma+1
Trials 1Status Recruiting
CGTLimited DatastaleKite, A Gilead CompanyPhase 2

Murine autologous anti-CD19 chimeric antigen receptor T cells (Murine autologous anti-CD19 chimeric antigen receptor T cells)

Acute Lymphoblastic Leukemia, Pediatric; Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

N-803 + Avelumab (N-803 + Avelumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

N-803 + Avelumab + PD-L1 t-haNK (N-803 + Avelumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

nivolumab (Opdivo, N-803 + Docetaxel + Nivolumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, N-803 + Docetaxel + Pembrolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

durvalumab (Imfinzi, N-803 + Durvalumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

durvalumab (Imfinzi, N-803 + Durvalumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting

74 / 103 pages

← PreviousNext →